How Much NAD+ Should I Give a 10 lb Older Dog?

By Richard Funk, DVM, CVA

✓ Medically reviewed by Richard Funk, DVM, CVA — August 28, 2026 For general education — not a substitute for veterinary care.

Aging Well · August 28, 2026 · 6 min read

For a 10 lb older dog, NAD+ precursor dosing follows the product label's small-dog tier, not a universal milligram figure.

The question I actually get asked

Owners rarely ask me “what is NAD+.” They ask me something narrower and more useful: their 10 lb terrier mix is eleven, she’s slower getting up from the rug, and a friend mentioned a chew with NAD+ precursors in it — so how much do they give her? I understand the instinct to want a number. But I start from the exam table, not the bottle, because a small senior’s joints and gait tell me more about what’s actually going on than a milligram figure ever will.

There is no single, veterinarian-established NAD+ dose for dogs the way there is for, say, a dewormer. What exists is product-specific labeling, generally tiered by body weight, built by the supplement maker rather than derived from a canine dosing trial. That distinction matters more than it sounds like it should.

Why NAD+ fades and why owners notice it in older, small dogs first

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme every cell needs to convert food into usable energy and to run DNA-repair enzymes called sirtuins and PARPs. Cellular NAD+ concentrations decline with age across mammals, and that decline is one proposed driver behind flagging energy and slower recovery in older dogs. Supplement makers respond to that biology by supplying precursor molecules — nicotinamide riboside (NR) chief among them — that cells can convert into NAD+, rather than dosing NAD+ itself, which doesn’t absorb well orally.

Small dogs often surface this earlier to their owners simply because they’re easier to carry, lift, and watch closely day to day; a 10 lb dog’s stiffness on stairs gets noticed sooner than the same change in a 70 lb dog whose owner isn’t hoisting her up.

What the label tiers are actually built on

Nicotinamide riboside has undergone real safety review. A National Center for Biotechnology Information: European Food Safety Authority assessment evaluated NR chloride as a novel food ingredient and found it did not raise safety concerns at the intake levels studied — though that review was built around human data, not canine dosing trials. Extrapolating a human-safe range down to a 10 lb dog by simple weight-scaling is a common industry shortcut, and it’s one I’m cautious about, because dogs metabolize compounds differently than people do across the board.

This is where label tiers earn their keep. A responsibly formulated product sets its “small dog” serving from its own safety and palatability data on that specific formulation — concentration, delivery form, other actives in the same chew — not from a generic mg/kg conversion an owner does with a calculator. When you’re weighing how much to give a 10 lb dog, the honest answer is: follow that product’s small-dog line on the label, confirm it against your dog’s actual weight, and don’t average two products’ doses together.

A scenario that shows why the tier matters

A colleague described a case that sticks with me: a 10 lb dachshund, nine years old, whose owner had been splitting an adult child’s leftover NR capsules in half because “it seemed like roughly the right ratio.” Three weeks in, the dog was having loose stools most mornings — not dramatic, but persistent enough that the owner assumed it was just aging. Once the dog switched to a product actually labeled for her weight class, the stools normalized within about ten days. Nothing about that dog’s NAD+ biology changed; what changed was that the dose finally matched a formulation tested for a dog her size, rather than a human capsule cut by eye. It’s a single case, not proof of anything general — but it’s a pattern I hear often enough to take seriously.

The counterargument, and why I still land on label-first dosing

The strongest pushback I hear is fair: “if the science is about NAD+ levels, why does the delivery vehicle matter so much?” It’s a reasonable question. The answer is that a chew isn’t a pure precursor dose — it’s a formulation with binders, flavoring, and often co-actives like quercetin or resveratrol, and its safety data was generated as that whole formulation, at that serving size, in that species. Quercetin, a flavonoid studied for antioxidant and cellular-support properties, and resveratrol are common co-ingredients in these longevity chews, and both are still active research areas rather than settled canine dosing science. One in vitro study found that quercetin, unformulated quercetin, NAC, and ascorbic acid, at the concentrations used, Pharmaceuticals (DOI.3390/ph19040525): did not affect the feeding behavior of the worms tested — a useful signal of tolerability at the cellular level, but not a canine dose-finding result. Separately, embryonic exposure to a resveratrol-related compound in another in vitro model Phytomedicine (DOI.1016/j.phymed.2026.158531): accelerated pupation and adult emergence but shortened adult lifespan — a reminder that “more antioxidant” is not automatically “better outcome,” even outside the dog. Given that uncertainty, I’d rather an owner slightly under-dose from a tested label tier than free-hand a number based on adult-human research.

Where the current commercial evidence actually stands

The most publicized canine data point in this space came from Animal Biosciences’ Leap Years supplement, developed with input from Harvard’s David Sinclair, which the company said improved measures of cognitive function and age-related decline in a company-run trial. That claim drew real scientific pushback: veterinary researcher Matt Kaeberlein publicly disputed the framing, and Animal Biosciences later walked back language describing the results as “proven to reverse aging in dogs,” a correction documented in SkeptVet: an evidence update from veterinarian Brennen McKenzie. I bring this up not to single out one brand, but because it’s the clearest recent example of how far marketing language can outrun what a trial actually showed — and it’s exactly why I tell owners to read the study behind a claim, not just the headline on the jar.

Applying this at home this week

Say your 10 lb dog is recovering from a mild ACL strain and her rehab plan already includes a joint supplement; you’re now weighing whether to layer in an NAD+ precursor chew too. This is where a musculoskeletal exam earns its place before any bottle does — a vet checking her gait, range of motion, and muscle symmetry can tell you whether her slowdown is orthopedic, neurologic, or more consistent with general age-related fatigue, and that distinction changes what’s worth adding, and in what order. Cornell University College of Veterinary Medicine: General guidance on joint supplement use from Cornell’s veterinary college makes a similar point: supplements support existing conditions, they don’t diagnose or replace an exam. Stacking two novel supplements at once also makes it hard to tell, three or four weeks later, which one is doing anything — introduce one at a time, at the labeled small-dog serving, and give it several weeks before judging.

If your dog’s slowdown traces more to gait and stiffness than flagging energy, our guide to hind leg weakness walks through how a vet sorts joint causes from nerve causes. If cognitive change — confusion, disrupted sleep, less interest in the household — is the bigger concern than energy, our overview of senior cognitive support supplements covers what the research actually supports there. And if you’re specifically comparing NAD+ precursor chews for an older dog whose energy dropped around age eight, we’ve written a closer look at that decision.

The short version for tonight

There isn’t a universal NAD+ milligram figure for a 10 lb dog — there’s a labeled small-dog serving on a specific, safety-reviewed formulation, and that’s what you follow, confirmed against her actual weight on the scale, not a guess from a bigger dog’s bottle. Start with one product, one dose, and a few weeks of watching. If her stiffness or slowdown looks orthopedic rather than just “low energy,” get the exam first — the joints and gait usually tell the real story before the supplement ever gets a chance to.